Discussion
Experimental Treatments for Myasthenia Gravis
Batoclimab
Batoclimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.
CABA-201
CABA-201 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a one-time intravenous, or into-the-bloodstream, infusion after a course of chemotherapy, the therapy is designed to target disease-driving immune B-cells to potentially reduce MG severity.
Cladribine
Cladribine is a short-course oral therapy being developed for generalized MG. Administered as oral capsules, it’s designed to lower the levels of the immune cells that drive inflammatory attacks in MG.
Descartes-08
Descartes-08 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions, it is designed to lower the levels of immune B-cells and potentially reduce disease severity.
DNTH103
DNTH103 is an investigational antibody-based therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system thought to contribute to disease’s autoimmune attacks.
Inebilizumab
Inebilizumab is an antibody-based therapy being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions every six months, the therapy is expected to reduce the levels of certain immune cells that drive MG and ease disease symptoms.
KYV-101
KYV-101 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a single infusion into the bloodstream, or intravenously, after a short course of chemotherapy, it is designed to lower the levels of immune B-cells and potentially ease disease severity.
MuSK-CAART
MuSK-CAART is an investigational T-cell therapy that’s being developed for the treatment of MG patients positive for anti-MuSK antibodies. Administered via a one-time intravenous, or into-the-vein, infusion, the therapy is designed to eliminate the specific immune B-cells that produce those self-reactive antibodies.
NMD670
NMD670 is an investigational oral therapy being developed for MG and a number of rare diseases. The therapy, administered twice daily in the form of oral tablets, is designed to improve nerve-muscle communication and restore muscle function.
Rituximab
Rituximab is an antibody-based therapy that’s approved for some blood cancers and autoimmune conditions. It is not formally approved for the treatment of MG, but it may be used off-label in some patients with treatment-resistant disease. The therapy is administered via intravenous, or into-the-vein, infusions.
Subcutaneous immunoglobulin
Subcutaneous immunoglobulin therapy is a type of immune-modulating treatment that’s normally used to manage a variety of immunodeficiency and autoimmune disorders. It’s not specifically approved to treat MG, but may be used off-label for managing the disease in some cases. It is administered via subcutaneous infusions.
Telitacicept
Telitacicept is an investigational B-cell targeting therapy being developed as a potential treatment for MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to reduce the activity of immune B-cells that drive MG.